<SEC-DOCUMENT>0001183740-23-000009.txt : 20230127
<SEC-HEADER>0001183740-23-000009.hdr.sgml : 20230127
<ACCEPTANCE-DATETIME>20230127171828
ACCESSION NUMBER:		0001183740-23-000009
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230127
FILED AS OF DATE:		20230127
DATE AS OF CHANGE:		20230127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BRIGHT MINDS BIOSCIENCES INC.
		CENTRAL INDEX KEY:			0001827401
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40997
		FILM NUMBER:		23564311

	BUSINESS ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		6474072515

	MAIL ADDRESS:	
		STREET 1:		19 VESTRY STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k-20230127drug.htm
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXY7CNC5JSVVG3MSDDP]. www.edgarsuite.com -->
<HEAD>
<TITLE>UNITED STATES</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:64.8pt;width:482.4pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>UNITED STATES</B><BR><B>SECURITIES AND EXCHANGE COMMISSION</B><BR><B>Washington, D.C. &nbsp;20549</B></P>
<P align=center style='font:14pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>FORM 6-K</B></P>
<P align=center style='font:12pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>For the month of <B>January 2023</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Commission File No. <B>001-40997</B></P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><FONT style='font-size:13pt;border-bottom:1px solid #000000'><B>BRIGHT MINDS BIOSCIENCES INC.</B></FONT><BR>(Translation of registrant's name into English)</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>19 Vestry Street,</B><BR><FONT style='border-bottom:1px solid #000000'><B>New York, NY &nbsp;10013</B></FONT><BR>(Address of principal executive office)</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</P>
<P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>Form 20-F</B>&#160;&#160;<B>[ X ]</B> &nbsp;Form 40-F<B>&#160;&#160;[ &nbsp;]</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &#160;[ &nbsp;]</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &#160;[ &nbsp;]</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin:0;background-color:#FFFFFF'><A name=_DV_M0 /><B>SUBMITTED HEREWITH</B></P>
<TABLE align=center style=border-collapse:collapse;width:475.45pt><TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:5.4pt;color:#000000'><FONT style='border-bottom:1px solid #000000'><B>Exhibits</B></FONT></P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:4.5pt;margin-right:7.65pt;color:#000000'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:56.95pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:5.4pt;color:#000000'>99.1</P>
</TD><TD valign=top style=width:418.5pt><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:6pt;margin-left:2.6pt;margin-right:1.95pt;color:#000000'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=ex991-20230127drug.htm style=text-decoration:none>News Release dated </A><A href=ex991-20230127drug.htm style=text-decoration:none>January 27, 2023</A></FONT></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
</DIV>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'><B>SIGNATURE</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><B>BRIGHT MINDS BIOSCIENCES INC.</B></P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt;margin-left:216pt'><I>/s/ Ryan Cheung</I><BR>__________________________<BR>Ryan Cheung<BR>Chief Financial Officer</P>
<P style='font:11pt Times New Roman;margin-top:12pt;margin-bottom:0pt'>Date:  January 27, 2023</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-20230127drug.htm
<DESCRIPTION>NEWS RELEASE
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2022 [PPXY7CNC5JSVVG3MSDDP]. www.edgarsuite.com -->
<HEAD>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt'><IMG src=ex99120230127drug_1.jpg width=113 height=88 alt=image1.png title=image1.png>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'><A name=_DV_M113 /><A name=_DV_M114 /><A name=_DV_M115 />&nbsp;</P>
<P align=center style='font:13pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><B>BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER REGARDING MINIMUM BID PRICE DEFICIENCY</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'><A name=_DV_M119 />Vancouver, British Columbia, January 27, 2023 &#8211;&nbsp;Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (&#8220;<B>Bright Minds</B>&#8221; or the &#8220;<B>Company</B>&#8221;) announces that it has received a notification letter (the &#8220;<B>Notification Letter</B>&#8221;) from the Nasdaq Stock Market LLC (&#8220;<B>NASDAQ</B>&#8221;) dated January 26, 2023, notifying the Company that due to thirty consecutive business days of closing bid prices for the common shares in the capital of the Company (the &#8220;<B>Shares</B>&#8221;) being below US$1.00 per Share, Bright Minds is not compliant with the minimum bid price requirement set forth in NASDAQ Listing Rule 5550(a)(2).</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>The Company has been provided 180 calendar days, being until July 25, 2023 (the &#8220;<B>Compliance Period</B>&#8221;), to regain compliance, which may be done by having a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days during the Compliance Period.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#000000'>The receipt of the Notification Letter has no immediate effect on the listing of the Company&#8217;s Shares, which will continue to trade uninterrupted on each of the Canadian Securities Exchange and NASDAQ under the symbol &#8220;DRUG&#8221;. &nbsp;To address the issue, the Company will continuously monitor its closing bid prices between now and July 25, 2023, and evaluate its options to regain compliance with NASDAQ Listing Rule 5550(a)(2) before such date. The Company anticipates resolving the deficiency within the compliance period.</P>
<P align=justify style='font:12pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><B>About Bright Minds</B></P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'>Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds&#8217; drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'><B>Investor Contacts:</B></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>Lisa Wilson</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt;color:#0000FF'><FONT style=color:#000000>E: </FONT><FONT style='border-bottom:1px solid #0000FF'>lwilson@insitecony.com</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>T: 917-543-9932</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>&nbsp;</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>Ian McDonald</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>CEO and Director</P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>E: <FONT style='color:#0000FF;border-bottom:1px solid #0000FF'>ian@brightmindsbio.com</FONT></P>
<P align=justify style='font:11pt Times New Roman;margin:0;margin-left:-9pt;margin-right:-4.5pt'>T: 917-543-9932</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>This news release includes certain statements that may be deemed &#8220;forward-looking statements&#8221;. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;potential&#8221; and similar expressions, or that events or conditions &#8220;will&#8221;, &#8220;would&#8221;, &#8220;may&#8221;, &#8220;could&#8221; or &#8220;should&#8221; occur. Forward-looking information in this news release includes statements related to future remedies of the Company&#8217;s non-compliance with NASDAQ Listing Rule 5550(2)(a), including its continuous monitoring of the closing price of the Shares or related actions that may be taken to regain compliance. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company&#8217;s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.</I></P>
<P align=justify style='font:11pt Times New Roman;margin-top:0pt;margin-bottom:8pt;margin-left:-9pt;margin-right:-4.5pt'><I>Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.</I></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99120230127drug_1.jpg
<TEXT>
begin 644 ex99120230127drug_1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< '<# 2(  A$! Q$!_\0
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MGZW=36T8N!*B(5&W[Q)]ZTK/PYX;M_BVJ6VFV,5Q/HKRWEFD:LD;^;'M;&,
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M2@$KSQ[9KSRM3Q')-/XEU.YGM)[1[BZDF\B=2KH&8L 0?K670 4444 %%%%
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
